Clinical Trials Directory

Trials / Conditions / Refractory Classic Hodgkin Lymphoma

Refractory Classic Hodgkin Lymphoma

12 registered clinical trials studyying Refractory Classic Hodgkin Lymphoma — 2 currently recruiting.

StatusTrialSponsorPhase
RecruitingAzacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
NCT06190067
Navy General Hospital, BeijingPhase 2
WithdrawnA Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in T
NCT05711628
National Cancer Institute (NCI)Phase 3
UnknownGLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (
NCT05518318
Guangzhou Gloria Biosciences Co., Ltd.Phase 3
Active Not RecruitingStudy of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
NCT04788043
Stanford UniversityPhase 2
RecruitingBrentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously
NCT05039073
Emory UniversityPhase 2
Active Not RecruitingCC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed
NCT05162976
City of Hope Medical CenterPhase 1
CompletedModified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refr
NCT04074746
M.D. Anderson Cancer CenterPhase 1 / Phase 2
Active Not RecruitingPembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
NCT03150329
City of Hope Medical CenterPhase 1
CompletedTesting the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medication
NCT02595866
National Cancer Institute (NCI)Phase 1
TerminatedNivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lym
NCT02408861
National Cancer Institute (NCI)Phase 1
Active Not RecruitingBrentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory
NCT01896999
National Cancer Institute (NCI)Phase 1 / Phase 2
CompletedCombination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That
NCT00967369
M.D. Anderson Cancer CenterPhase 2